LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Listă Acțiuni・Gilead Sciences Inc.

Gilead Sciences Inc.

Închisă

SectorSănătate

129.52 -1.92

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

129.01

Maxim

132.62

Indicatori cheie
By Trading Economics
Venit	-162M 2B
Vânzări	-965M 7B
P/E Medie Sector	18.191 51.415
EPS	2.03
Randament dividend	2.43
Marjă de profit	29.037
Angajați	17,000
EBITDA	18M 2.4B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+20.13% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	2.43% 2.34%
Următoarele câștiguri	6 aug. 2026
Data viitoare de dividende	29 iun. 2026
Următoarea dată ex-dividende	15 iun. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1.1B 166B
Deschiderea anterioară	131.44
Închiderea anterioară	129.52

Sentimentul știrilor

By Acuity

28%

72%

62 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

97.33 / 103.17 Suport & Rezistență

Gilead Sciences Inc. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 mai 2026, 20:49 UTC

Câștiguri

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

7 apr. 2026, 14:24 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

7 apr. 2026, 12:53 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

8 mai 2026, 08:10 UTC

Câștiguri

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

8 mai 2026, 08:08 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 22:33 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mai 2026, 21:09 UTC

Câștiguri

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 mai 2026, 20:51 UTC

Câștiguri

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

7 mai 2026, 20:06 UTC

Câștiguri

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

7 mai 2026, 20:05 UTC

Câștiguri

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

7 mai 2026, 20:05 UTC

Câștiguri

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

7 mai 2026, 20:02 UTC

Câștiguri

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

7 mai 2026, 20:01 UTC

Câștiguri

Gilead Sciences 1Q Rev $6.96B >GILD

7 mai 2026, 20:01 UTC

Câștiguri

Gilead Sciences 1Q Adj EPS $2.03 >GILD

7 mai 2026, 20:01 UTC

Câștiguri

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

7 mai 2026, 20:01 UTC

Câștiguri

Gilead Sciences 1Q EPS $1.61 >GILD

28 apr. 2026, 12:45 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

17 apr. 2026, 12:32 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

17 apr. 2026, 12:30 UTC

Achiziții, Fuziuni, Preluări

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

7 apr. 2026, 14:36 UTC

Achiziții, Fuziuni, Preluări

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

7 apr. 2026, 14:35 UTC

Achiziții, Fuziuni, Preluări

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

7 apr. 2026, 14:34 UTC

Achiziții, Fuziuni, Preluări

EQT Life Sciences: Gilead Will Also Buy TUB-030

7 apr. 2026, 14:28 UTC

Achiziții, Fuziuni, Preluări

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

7 apr. 2026, 14:23 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Gilead Buying Another Cancer-Drug Partner -- Market Talk

7 apr. 2026, 13:55 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

7 apr. 2026, 13:14 UTC

Achiziții, Fuziuni, Preluări

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

7 apr. 2026, 12:30 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

7 apr. 2026, 12:30 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

7 apr. 2026, 12:30 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

7 apr. 2026, 12:30 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Tubulis Deal Includes $3.15B Upfront Cash Consideration on Cash-Free, Debt-Free Basis >GILD

Comparație

Modificare preț

Gilead Sciences Inc. Așteptări

Obiectiv de preț

By TipRanks

20.13% sus

Prognoză pe 12 luni

Medie 159.83 USD 20.13%

Maxim 180 USD

Minim 122 USD

În baza a 22 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGilead Sciences Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

22 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 22 analiști care au acordat evaluări ale acțiunilor Gilead Sciences Inc. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

97.33 / 103.17Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bullish event.

Sentiment

By Acuity

62 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.